Brokerages Anticipate Jazz Pharmaceuticals PLC (JAZZ) to Post $2.89 Earnings Per Share
Equities research analysts forecast that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will report $2.89 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Jazz Pharmaceuticals PLC’s earnings, with the lowest EPS estimate coming in at $2.78 and the highest estimate coming in at $2.98. Jazz Pharmaceuticals PLC reported earnings per share of $2.57 in the same quarter last year, which suggests a positive year over year growth rate of 12.5%. The company is scheduled to report its next quarterly earnings report after the market closes on Tuesday, November 7th.
According to Zacks, analysts expect that Jazz Pharmaceuticals PLC will report full year earnings of $10.92 per share for the current year, with EPS estimates ranging from $10.71 to $11.05. For the next year, analysts anticipate that the business will post earnings of $12.99 per share, with EPS estimates ranging from $11.74 to $14.80. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). The company had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.67 EPS.
Several analysts have weighed in on the stock. Royal Bank Of Canada reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. Piper Jaffray Companies set a $182.00 price target on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Friday, July 14th. Deutsche Bank AG set a $178.00 price target on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Monday, July 17th. Wells Fargo & Company restated an “outperform” rating and set a $177.00 price target (down previously from $178.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. Finally, Cowen and Company restated an “outperform” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $180.88.
In other Jazz Pharmaceuticals PLC news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $150.00, for a total value of $150,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Paul Treacy sold 1,304 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $143.32, for a total transaction of $186,889.28. The disclosure for this sale can be found here. Insiders sold a total of 4,517 shares of company stock valued at $665,623 over the last three months. 4.30% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Toronto Dominion Bank lifted its holdings in Jazz Pharmaceuticals PLC by 12.4% in the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after acquiring an additional 81 shares during the last quarter. US Bancorp DE lifted its holdings in Jazz Pharmaceuticals PLC by 94.4% in the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after acquiring an additional 368 shares during the last quarter. Gargoyle Investment Advisor L.L.C. acquired a new stake in Jazz Pharmaceuticals PLC in the 2nd quarter valued at about $206,000. Janney Montgomery Scott LLC acquired a new stake in Jazz Pharmaceuticals PLC in the 2nd quarter valued at about $211,000. Finally, Brighton Jones LLC acquired a new stake in Jazz Pharmaceuticals PLC during the 2nd quarter worth about $213,000. 88.55% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Jazz Pharmaceuticals PLC (JAZZ) to Post $2.89 Earnings Per Share” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/11/03/brokerages-anticipate-jazz-pharmaceuticals-plc-jazz-to-post-2-89-earnings-per-share.html.
Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded down $3.58 during trading on Friday, reaching $137.89. The company’s stock had a trading volume of 287,844 shares, compared to its average volume of 449,324. The stock has a market capitalization of $8.23 billion, a P/E ratio of 19.02 and a beta of 1.00.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.